Condition: High Grade Glioma · Diffuse Intrinsic Pontine Glioma · Recurrent Medulloblastoma · Sponsor: Nationwide Children's Hospital
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB). PEP-CMV is a vaccine mixture of a peptide referred to as Component A. Component A is a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. The SLPs encode multiple potential class I, class II, and antibody epitopes across several haplotypes. Component A will be administered as a stable water:oil emulsion in Montanide ISA 51. Funding Source - FDA OOPD
This description comes directly from the study's public registry record.
Kelsey H Troyer, PhD · 6147223284 · kelsey.troyer@nationwidechildrens.org
Always discuss trial participation with your own doctor first.
| Children's Hospital Colorado | Aurora, Colorado, United States | Recruiting |
| Children's National Medical Center | Washington D.C., District of Columbia, United States | Recruiting |
| Nicklaus Children's Hospital | Miami, Florida, United States | Recruiting |
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Not Yet Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Not Yet Recruiting |
| C.S. Mott Children's Hospital | Ann Arbor, Michigan, United States | Recruiting |
| St. Louis Children's Hospital | St Louis, Missouri, United States | Recruiting |
| Duke Cancer Center | Durham, North Carolina, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
| Nationwide Children's Hospital | Columbus, Ohio, United States | Recruiting |
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Not Yet Recruiting |
| Texas Children's Hospital | Houston, Texas, United States | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05096481